The Turnover and Transport of Vitamin D and of a Polar Metabolite with the Properties of 25-Hydroxycholecalciferol in Human Plasma

JOHN EDGAR SMITH and DEWITT S. GOODMAN

From the Department of Medicine, Columbia University College of Physicians and Surgeons, New York 10032

ABSTRACT Four normal men were injected intravenously with physiological doses (6 μg) of vitamin D-1,2-3H. Serial samples of plasma were collected for 50 days. Total lipid extracts were chromatographed on silicic acid columns or thin-layer plates in order to characterize the radioactive components. Labeled vitamin D3 disappeared rapidly from plasma (initial half-life approximately 12 hr); after 7 days unchanged vitamin D3 represented less than 1% of circulating radioactivity. Coincident with vitamin D3 disappearance a more polar labeled metabolite appeared with chromatographic properties identical with those of 25-hydroxycholecalciferol. The disappearance of the more polar metabolite was relatively slow with a half-life of 19.6 ±0.6 days.

A similar half-life was seen in a fifth subject, injected with 80 μg of vitamin D3-3H. Most (approximately 92%) of the plasma total radioactivity was represented by this component throughout the study. Plasma samples collected at various times were adjusted to density (d) 1.21 and were ultracentrifuged to separate plasma lipoproteins from proteins with d > 1.21. In all samples, almost all (mean 94%) of the radioactivity was found in association with proteins of d > 1.21. This observation was confirmed by bioassay, measuring uptake of 45Ca by intestinal slices. All plasma bioassayable vitamin D was found in association with proteins of d > 1.21; 55% of bioactivity was found in the chromatographic fraction corresponding to 25-hydroxycholecalciferol and 44% in the fractions representing vitamin D3. Since both vitamin D3 and its 25-hydroxy metabolite are lipid-soluble sterol derivatives, the finding that these compounds do not circulate in association with the known plasma lipoproteins provides presumptive evidence for the existence of a specific transport protein of d > 1.21. The transport protein for the polar metabolite has been partly characterized by gel filtration on Sephadex G-200 and by electrophoresis on polyacrylamide gel. The protein has an apparent size slightly smaller than plasma albumin (approximately mol wt 50,000–60,000) and an electrophoretic mobility very slightly greater than that of albumin. Studies are in progress to fractionate further and to characterize the transport protein.

INTRODUCTION

Recent studies of vitamin D metabolism have demonstrated that vitamin D is rapidly converted into a more polar metabolite after its intravenous injection into humans (1) or other animals (2–4). This metabolite, isolated from swine plasma, was identified as 25-hydroxycholecalciferol by Blunt, DeLuca, and Schnoes (3), and was shown to be biologically more active than cholecalciferol (vitamin D3) itself. The conversion of vitamin D3 to its 25-hydroxy “active” metabolite appears to occur in the liver (2) and may be an essential step in the activation of vitamin D for target tissues such as the intestinal mucosa (5) or bone (6). After its formation, 25-hydroxycholecalciferol is presumably transported from the liver to the target tissues where still more polar metabolites are formed and found (7–9) and where biological effects occur. It has also been suggested recently by Fraser and Kodicek (10) and confirmed by DeLuca (11) that the kidney is the site of conversion of 25-hydroxycholecalciferol to a still more polar active metabolite which is found in intestinal mucosa.*

Dr. Smith is a trainee under grant TL-AM-05397 from the National Institutes of Health, U. S. Public Health Service. Dr. Goodman is a Career Scientist of the Health Research Council of the City of New York under contract 1-399.

Received for publication 11 March 1971 and in revised form 7 April 1971.

*Note added in proof: This metabolite has very recently been identified as 1,25-dihydroxycholecalciferol [Lawson, D. E. M., D. R. Fraser, E. Kodicek, H. R. Morris, M. J. Rodgers].
Limited information is available about the turnover and the plasma transport of vitamin D₃ and of its 25-hydroxy metabolite. In 1967, Avioli, Lee, McDonald, Lund, and DeLuca reported that cholecalciferol-²¹H disappeared rapidly from the plasma of normal subjects with a half-life of 20-30 hr (1). Coincident with the disappearance of cholecalciferol, a more polar metabolite with the properties of 25-hydroxycholecalciferol appeared. A slower plasma disappearance rate of vitamin D₃-²¹H and a reduction in the amount of label appearing as the polar metabolite were observed in patients with vitamin D-resistant rickets (12). More recently, Mawer, Lumb, and Stanbury reported that, after the initial rapid disappearance of labeled vitamin D₃ from human plasma, a prolonged second phase was seen with a half-life of 20-44 days (13). A large proportion of the radioactivity found in plasma during the slow second phase was present as polar metabolites. In this study the amounts of labeled vitamin D injected were 10-20 times the recommended daily allowance for vitamin D (14).

Before the isolation and identification of 25-hydroxycholecalciferol, several studies were conducted to examine the transport of vitamin D in human (15-17) and in rat (18, 19) serum. Human serum proteins were separated by agar-gel electrophoresis by de Crousaz, Blanc, and Antener, who found vitamin D activity, by bioassay, in the albumin and α-globulin fractions (16). Thomas et al. also found vitamin D activity in association with the α-globulin and albumin fractions of human serum (15). Using labeled vitamin D₃, Rikkers and DeLuca found that both the vitamin and its polar metabolite were associated with several protein bands, but particularly with an α-globulin, after disc gel electrophoresis (19). No information is available about the plasma transport of 25-hydroxycholecalciferol in man.

We now report a study of the turnover of vitamin D₃ and of its polar metabolite in humans after the administration of small, physiological doses of the labeled vitamin. The transport of the vitamin and particularly of its polar metabolite has been examined in some detail. Neither the vitamin nor its polar metabolite circulates in association with the known plasma lipoproteins. The transport protein for the polar metabolite has been partly characterized with regard to apparent molecular size and to electrophoretic mobility.

METHODS

Experimental design. Five normal male volunteers, 24-28 yr of age, participated in this study. All subjects ate their usual diets throughout the studies; none of them received, or had been taking, vitamin supplements. Each subject was given an intravenous injection of ¹⁴C-labeled cholecalciferol. Serial samples of blood were collected, after 1, 2, 4, 7, 10, and 15 days, and then at weekly intervals for a total of 7-8 wk, in syringes moistened with a solution of heparin. Relatively large samples, of approximately 100 and 500 ml, were collected on the 2nd and 7th days, respectively, for attempted fractionation of the transport protein. Blood cells were sedimented by centrifugation at 2000 rpm for 30 min at 4°C. Portions of the plasma samples were then either extracted with CHCl₃-CH₃OH (see below), subjected to ultracentrifugation in order to separate lipoproteins from other plasma proteins (see below), or stored in the frozen state at -20°C for later study.

In the first, preliminary experiment, subject C. H. was given 80 µg (7.36 µCi) of cholecalciferol-¹³C-²¹H₂ (specific radioactivity 354 mCi/m mole) dissolved in 0.7 ml absolute ethanol in a manner similar to that of Avioli and coworkers (1, 12). The radioactive purity of the injected material exceeded 90% as assessed by thin-layer chromatography (TLC).

In the second and major study, each of four subjects received 6 µg (2.36 µCi) of a high specific radioactivity (154 mCi/m mole) preparation of cholecalciferol-¹³C-²¹H₂ dispersed in an isotonic NaCl solution. The cholecalciferol-²¹H was purified by TLC on silica gel, using benzene-ethyl acetate, 3:1 (v/v) as solvent just before use. The purified cholecalciferol-²¹H was dissolved in 1 ml of ethanol, and under sterile conditions was dispersed through a No. 26 hypodermic needle into 20 ml of sterile 0.9% NaCl solution. Each subject was injected with 4.5 ml of the final dispersion.

Extraction and chromatography. Samples of whole plasma or of plasma fractions were extracted with 20 volumes of CHCl₃-CH₃OH, 2:1 (v/v) containing 1 mg of butylated hydroxytoluene (BHT) per 100 ml as an antioxidant.


2Abbreviations used in this paper: BHT, butylated hydroxytoluene; RBP, retinol-binding protein; TLC, thin-layer chromatography; TMS, trimethylsilyl.

<p>| TABLE I |</p>
<table>
<thead>
<tr>
<th>Elution Scheme Employed for Silicic Acid Column Chromatography</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fraction</td>
</tr>
<tr>
<td>No.</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>5</td>
</tr>
<tr>
<td>6</td>
</tr>
<tr>
<td>7</td>
</tr>
<tr>
<td>8</td>
</tr>
<tr>
<td>9</td>
</tr>
<tr>
<td>10</td>
</tr>
<tr>
<td>11</td>
</tr>
</tbody>
</table>

* 21% benzene in hexane means benzene-hexane, 21:79 (v/v); 10% methanol in chloroform means methanol-chloroform, 1:9; etc. ²Plasma sample obtained from subject F.B. 24 hr after the intravenous administration of 6 µg cholecalciferol-1,2-²¹H. ³Plasma sample obtained from subject F.B. 24 hr after the intravenous administration of 6 µg cholecalciferol-1,2-²¹H.
mg of unlabeled carrier cholecalciferol a was added to each extraction. Each extraction mixture was split into two phases by addition of 5 volumes of 0.05% H2SO4, and the entire CHCl3 phase was collected and evaporated to dryness under a stream of nitrogen. Portions of the total lipid extracts so obtained were assayed directly for radioactivity; other portions were subjected to column or thin-layer chromatography.

Column chromatography was performed with amber glass columns of 1 cm diameter containing 5 g of silicic acid (Unisol, 100-200 mesh). b 11 fractions were eluted from each column in a stepwise procedure as shown in Table I. This elution scheme is a modification of the elution schemes employed in this laboratory for the separation of plasma neutral lipids and phospholipids (20, 21). The scheme shown in Table I was designed to achieve a clear separation of mono-hydroxy sterols (e.g. cholecalciferol) and di-hydroxy sterols (e.g. 25-hydroxycholecalciferol) from each other and from still more polar lipids. Experiments with pure reference compounds demonstrated that, in this scheme, cholecalciferol is eluted in fractions 3, 4, and 5, and 25-hydroxycholecalciferol in fraction 8. During this study the mean (% recovered) recovery of radioactivity applied to the columns was 102 ±2% for 47 chromatographic runs.

Portions of the total lipid extracts of the proteins with density (d) greater than 1.21 were chromatographed on silica gel thin-layer plates c with benzene-ethyl acetate, 3:1, in an atmosphere of nitrogen and in the dark. Carrier 25-hydroxycholecalciferol d was added to some but not all samples before TLC. After chromatography the plates were lightly sprayed with a solution of Rhodamine 6G, and the separated cholecalciferol (Rf 0.55-0.6) and 25-hydroxycholecalciferol (Rf 0.30) bands were visualized under ultraviolet light, scraped, and eluted with chloroform. The remainder of the plate was divided into bands of approximately 1 cm width, which were each scraped and eluted. The eluates were evaporated and assayed for radioactivity.

Trimethylsilyl (TMS) ether derivatives. TMS ether derivatives of the total lipid extracts of the proteins of d > 1.21 were prepared from the plasma samples collected from subjects A. B. and F. B. 36 days after the injection of cholecalciferol-\(^{4}H\). 1 mg of carrier 25-hydroxycholecalciferol was added to the extraction mixture for each of these samples. The total lipid extract was suspended in 200 ml of a solution of pyridine-hexamethyldisilazane-trimethylchlorosilane, 9:3:1 (22) (Sil-prep) e and allowed to react for 60 min. Portions of the reaction mixtures were then subjected to TLC on silica gel plates in two different systems: (a) benzene-ethyl acetate, 3:1, and (b) two-directionally with benzene-hexane, 1:1, followed at right angles by methyl ethyl ketone-acetonitrile, 7:3, 80% saturated with mineral oil. The area of the carrier was located as described above, and the scraped bands or spots were eluted with hot benzene-ethyl ether, 1:1.

Separation of lipoproteins. Plasma lipoproteins were separated from proteins with hydrated density greater than 1.21 by ultracentrifugation, using a simplified modification of the method of Havel, Elliot, and Bragdon (23). For each separation, 10 ml of fresh plasma was placed in a 3 x 3 in. polycoroller tube containing 3.328 g of KBr. After the KBr had dissolved, the tubes were filled with a d 1.21 solution of KBr-NaCl and centrifuged in a No. 40 rotor of a Spinco model L ultracentrifuge at 40,000 rpm for 36-48 hr. The tubes were sliced in the clear zone, and the floating (lipoprotein, d < 1.21) and sedimenting (d > 1.21) fractions were collected separately.

**Gel filtration and electrophoresis.** Gel filtration was carried out on columns of Sephadex G-200 f in a cold room at 4°-5°C. The columns were eluted with 0.02 m phosphate buffer, pH 7.3, containing 0.2 m NaCl. The size of the column varied in different experiments, but the volume of the sample applied was restricted to 3% or less of the column bed volume. The samples subjected to gel filtration included the following: (a) a large sample of pooled plasma obtained from subjects A. B., F. B., R. H., and T. L. on the 7th day after the injection of cholecalciferol-\(^{4}H\); (b) plasma obtained from subject C. H. on the 15th day after injection; and (c) a pooled sample of plasma obtained from subject C. H. on the 5th, 27th, and 34th days of study.

Preparative polyacrylamide gel electrophoresis was performed with a Buchler f "poly-prep 200" apparatus as described previously (24).

**Other procedures.** Radioassay for \(^{4}H\) was carried out by dissolving samples in 15 ml of 0.5% diphenyloxazole in toluene followed by assay with a Packard liquid scintillation

---

a Schwarz Bio Research Inc., Orangeburg, N. Y.
b Clarkson Chemical Co., Inc., Williamsport, Pa.
c Brinkmann Instruments Inc., Westbury, N. Y.
d A generous gift of the Upjohn Co., Kalamazoo, Mich., courtesy of Dr. John C. Baecock.

---

*Pharmacia Fine Chemicals Inc., Piscataway, N. J.*
*Buchler Instruments, Inc., Fort Lee, N. J.*
*Nutritional Biochemicals Corporation, Cleveland, Ohio.*
*Camn Research Institute, Inc., Wayne, N. J.*

**Vitamin D Turnover and Transport in Man** 2161
Figure 1 The turnover of plasma vitamin D after the injection of 6 μg of cholecalciferol-4H into each of four subjects. The points show the mean ± SEM values (in brackets) for plasma total radioactivity, and for plasma-4H recovered in the cholecalciferol-containing fractions (labeled: vitamin D₄) and in the 25-hydroxycholecalciferol-containing fraction (labeled: fraction 8) after silicic acid column chromatography.

counter. Quenching was corrected for, where appropriate, by means of an automatic external standardization system.

Saponification of the total lipid extract of a d > 1.21 sample was conducted in 2.15 ml of 2.2% KOH in 63% ethanol at 65°–70°C under nitrogen for 2 hr. 1 ml of water was added, and the nonsaponifiable lipids were collected by three extractions, each time with 5 ml of hexane.

The half-life of the slow, semilogarithmic disappearance of radioactivity from plasma (see Results) was determined for each subject on the eight observations made between the 4th and 50th days after the injection of cholecalciferol-4H. For subject C. H. nine observations between the 7th and 56th days were used. Linear regression lines of the logarithm of the concentration of radioactivity vs. time in days were calculated by the method of least squares (28), using a Wang* model 700 electronic calculator. The half-lives were calculated from the regression lines.

RESULTS

Turnover of radioactive vitamin D₄. Fig. 1 shows the results obtained with the four subjects who were injected with 6 μg of cholecalciferol-4H. The semilogarithmic plot of the concentration of plasma total radioactivity vs. time described a curve during the first 4 days, whereas beyond this time the plot followed a straight line.

Extracts of each of the plasma samples collected in this study were analyzed by silicic acid column chromatography. In all samples, quantitatively significant amounts of 4H were only recovered in the cholecalciferol-containing fractions (fraction 3 + 4 + 5) and in the 25-hydroxycholecalciferol-containing fraction (fraction 8). A small amount of 4H was also consistently recovered in fraction 10, which contained a mean (± SEM) of 2.4 ± 0.3% of the recovered 4H for the samples analyzed. (See Table I for a representative example.) No infor-
On TLC in benzene–ethyl acetate, 3:1, the radioactivity in column fraction 8 was found to comigrate with authentic 25-hydroxycholecalciferol. In a representative experiment, a pooled extract of plasma proteins of d > 1.21 obtained 48 hr after injection was analyzed by TLC. 11% of the \(^{3}H\) cochromatographed with carrier cholecalciferol and 83%, with carrier 25-hydroxycholecalciferol. The remaining very small amount (6%) of the radioactivity was mainly smeared throughout the area from the origin to the 25-hydroxycholecalciferol band. On silicic acid column chromatography of an extract of this pool of whole plasma, 13% of the \(^{3}H\) was eluted in the cholecalciferol-containing fractions (fractions 3 + 4 + 5) and 81% in fraction 8.

TMS ether derivatives were formed with the extracts of two samples obtained on the 36th day of the study, which contained 89% of their \(^{3}H\) content as the polar metabolite (eluted in column fraction 8) (see Methods). On subsequent TLC, most of the \(^{3}H\) cochromatographed with the simultaneously formed TMS ether derivative of authentic carrier 25-hydroxycholecalciferol. After TLC in benzene–ethyl acetate (3:1) 81 and 85% (for the two samples) of the recovered \(^{3}H\) cochromatographed with the TMS carrier band (\(R_f\) 0.88); the remaining radioactivity was spread in a broad trailing zone behind this band. After two-dimensional TLC, 58% and 73% of the recovered \(^{3}H\) (for the two samples) cochromatographed with the TMS carrier spot. Since the recovery of the TMS derivative of 25-hydroxycholecalciferol after its formation and TLC was not expected to be quantitative, these data support the conclusion that the labeled metabolite in column fraction 8 had properties virtually identical with those of 25-hydroxycholecalciferol.

By saponification it was confirmed that the polar metabolite was not an ester or other saponifiable derivative of vitamin D\(_{3}\). A sample of plasma proteins of d > 1.21 was obtained from subject C. H. 56 days after injection of cholecalciferol–\(^{3}H\). After extraction and silicic acid column chromatography, 96% of the \(^{3}H\) in this sample was recovered in the 25-hydroxycholecalciferol-containing fraction. After saponification of a portion of this extract, 98% of the \(^{3}H\) was recovered with the nonsaponifiable lipids. The labeled nonsaponifiable lipid was eluted from a silicic acid column in a pattern identical with that seen for the labeled lipid in the extract before saponification (96% of the \(^{3}H\) recovered in the 25-hydroxycholecalciferol-containing fraction).

**Ultracentrifugation at density 1.21.** Plasma samples were separated into lipoproteins (d < 1.21) and proteins of density greater than 1.21 at several times during the study. The distribution of radioactivity between these two fractions, for the subjects who were given 6 \(\mu\)g of cholecalciferol–\(^{3}H\), is shown in Table III. Almost all (>90%, mean 94%) of the \(^{3}H\) was consistently found to be associated with the proteins of density greater than 1.21. In these four subjects, slightly more radioactivity (mean of 8% of total \(^{3}H\)) was found in the lipoprotein fractions (d < 1.21) at 2 days after isotope injection than at later intervals. On column chromatography of extracts of the 2-day samples, relatively more of the \(^{3}H\) in the lipoprotein fractions than in the d > 1.21 fractions was found as esterified and as unchanged vitamin D\(_{3}\). Similarly, with the subject who received the 80 \(\mu\)g dose, 90, 97, and 98% of the plasma total \(^{3}H\) was found associated with the proteins of density greater than 1.21 after 5, 19, and 56 days, respectively. In this subject, during the interval 12 hr–3 days (four samples) 81–87% of the \(^{3}H\) was found in the d < 1.21 fraction. The results with the earliest samples collected suggest that a very small portion of the injected labeled vitamin D\(_{3}\) was circulating in association with the plasma lipoproteins during the early time intervals. Most of the vitamin D\(_{3}\), however, and virtually all of the polar metabolite with the properties of 25-hydroxycholecalciferol circulated in association with the proteins of density greater than 1.21 and not with the known plasma lipoproteins. This conclusion was confirmed by bioassay (see below).

**Gel filtration.** Gel filtration on Sephadex G-200 was performed with three plasma samples, each containing almost all of its radioactivity as the polar metabolite (see Methods for more details). These experiments provide information about the apparent molecular size of the transport protein for the polar metabolite. The results of a representative experiment are shown in Fig. 2. An identical elution pattern was obtained in each of five chromatographic runs. In each instance, almost all of the radioactivity was eluted in a peak with an elution volume very close to that of plasma albumin. The center of the peak of radioactivity was consistently found to be eluted very slightly after the center of the plasma albumin peak (see Fig. 2). These results suggest that the polar metabolite

<table>
<thead>
<tr>
<th>Fraction</th>
<th>Distribution of radioactivity(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipoproteins (d &lt; 1.21)</td>
<td>6.1 ± 0.8</td>
</tr>
<tr>
<td>Proteins with d &gt; 1.21</td>
<td>93.9 ± 0.8</td>
</tr>
</tbody>
</table>

* 14 samples were analyzed, which were collected from subjects A. B., F. B., R. H., and T. L. 2, 4, and 7 days after the injection of label, and from subjects R. H. and T. L. after 36 days.

\(\dagger\) Mean ± SEM.

**Table III: Distribution of Radioactive Vitamin D after Ultracentrifugation at Density 1.21**
of vitamin D₃ circulates in association with a protein of apparent molecular size very close to, but slightly smaller than, that of human plasma albumin.

**Preparative polyacrylamide gel electrophoresis.** The fractions comprising the ³H-containing peak after gel filtration were combined, and the protein was then subjected to preparative polyacrylamide gel electrophoresis.

As shown in Fig. 3, the radioactivity migrated in a single sharp peak with a mobility very slightly greater than that of plasma albumin. In each of three experiments, the peak of radioactivity was found to be mainly located along the leading edge of the albumin peak. The mobility of the ³H-containing peak was distinctly less than that of plasma prealbumin, but considerably more than that of proteins with α-mobility. The fractions containing the proteins with α-mobility, identified by the fluorescence of retinol-binding protein (24), contained only 4% of the total radioactivity.

**Bioassay.** The results of a bioassay study are presented in Table IV. In this experiment, virtually all of the biological activity of whole plasma was recovered after ultracentrifugation at density 1.21, in association with the sedimenting proteins of density greater than 1.21. Slightly more than half of the biological activity of plasma was found in fraction 8 after silicic acid column chromatography of an extract of plasma; the remainder was found in the cholecalciferol-containing fractions (fractions 3 + 4 + 5).

These observations were confirmed in a later experiment using plasma collected from a normal 34 yr old male subject who had not been injected with labeled cholecalciferol. In this subject, the vitamin D activity of an extract of whole plasma was equivalent to 26 ng of cholecalciferol per ml of plasma. After ultracentrifugation, an extract of the proteins with d > 1.21 contained bioactivity equivalent to 21 ng of cholecalciferol per ml of plasma. The compounds recovered in fractions 3 + 4 + 5 and in fraction 8, after silicic acid column chromatography, had bioactivity equivalent to 9 and 11 ng of cholecalciferol per ml of plasma, respectively.

**Table IV**

<table>
<thead>
<tr>
<th>Sample assayed*</th>
<th>Distribution of total bioassayable activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole plasma</td>
<td>100</td>
</tr>
<tr>
<td>Lipoproteins (d &lt; 1.21)</td>
<td>0</td>
</tr>
<tr>
<td>Proteins with d &gt; 1.21</td>
<td>100</td>
</tr>
<tr>
<td>Fractions 3 + 4 + 5†</td>
<td>44</td>
</tr>
<tr>
<td>Fraction 8‡</td>
<td>55</td>
</tr>
</tbody>
</table>

* The samples assayed were derived from a sample of pooled plasma collected from subjects A. B., F. B., and R. H. on the 50th day of the study. The pooled plasma was estimated to contain a total vitamin D activity equivalent to 18 ng of cholecalciferol per ml.

† After silicic acid column chromatography of an extract of whole plasma.

**FIGURE 2** Gel filtration of whole plasma containing radioactive vitamin D metabolites. 6 ml of whole plasma from a sample of pooled plasma collected from four subjects on day 7 (see Methods) was dialyzed successively three times, each time against 4 liters of 0.02 M Na phosphate buffer, pH 7.3, containing 0.2 M NaCl. The dialyzed sample was applied to a 2.5 × 63 cm column (bed volume, 309 ml) of Sephadex G-200. The elution was conducted with the same buffer at a flow rate of 15 ml/hr. Fractions of 3 ml each were collected.

**FIGURE 3** Preparative polyacrylamide gel electrophoresis. The fractions comprising the ³H-containing peak after gel filtration (e.g. fractions 50-66 in Fig. 2) of the pooled sample from subject C. H. were concentrated by ultrafiltration (Diaflow UM-2 membrane; Amicon Corp., Lexington, Mass.) and dialyzed against water. 8 ml of the concentrated sample containing 10 mg of protein per ml in 5% sucrose was applied to a 9.5 cm high column of 7% acrylamide gel. The electrophoresis was conducted at a constant voltage of 400 V and approximately 20 mA, with an elution rate of 40 ml/hr. Fractions of 6 ml were collected.

2164  J. E. Smith and DeW. S. Goodman
DISCUSSION

The studies reported here demonstrate that the labeled polar metabolite which appears in plasma after the injection of radioactive vitamin D₃ has a relatively slow turnover with a half-life of 19.6 ±0.6 days. In these studies, four of the five subjects were injected with a small, physiological dose (6 µg) of vitamin D₃, which was well within the recommended daily allowance of vitamin D (14). After injection the labeled vitamin D₃ disappeared rapidly from plasma, with an initial half-life of approximately 12 hr. After 7 days, labeled unchanged vitamin D₃ represented less than 1% of the circulating radioactivity. Coincident with the disappearance of labeled vitamin D₃ a more polar component appeared, with chromatographic and other properties of 25-hydroxycholecalciferol. Most (approximately 92%) of the plasma total radioactivity was represented by this component throughout the later part of the study.

The properties of the labeled polar metabolite were compared directly with those of authentic 25-hydroxycholecalciferol. The labeled metabolite cochromatographed with 25-hydroxycholecalciferol on silicic acid columns and on thin layers of silica gel. The two components also cochromatographed during TLC in two different systems after formation of the TMS ether derivatives. Finally, the labeled polar metabolite was shown to be a non-saponifiable lipid whose chromatographic properties were not altered by saponification. These findings indicate that the labeled polar metabolite in plasma was either 25-hydroxycholecalciferol itself or an extremely similar compound with properties identical with those of 25-hydroxycholecalciferol in the systems examined (or a mixture of such nearly identical compounds). In view of the demonstrated biological activity of the fraction containing the polar metabolite, it is reasonable to conclude that the labeled polar metabolite was probably 25-hydroxycholecalciferol.

A slow disappearance of plasma total radioactivity, after the injection of labeled vitamin D₃ into human subjects, has been reported by Mawer et al. (13). In contrast with our findings, however, Mawer et al. reported that after the initial rapid disappearance of labeled vitamin D₃ from plasma and the appearance of labeled polar metabolites, both the unchanged vitamin D₃ and its polar metabolites exhibited a prolonged phase with a slow turnover rate. The half-life of labeled vitamin D₃ during this later phase of slow turnover was 18–36 days, while that of plasma total radioactivity was 20–44 days (13). The differences between these observations and our own may possibly be explained by the relatively large doses of labeled vitamin D₃ (110 and 216 µg) injected by Mawer et al. Consistent with this explanation is our finding that the disappearance rate of labeled vitamin D₃ in the subject who received an 80 µg dose was consider-

ably slower and more prolonged than that seen in the subjects who were given 6 µg. This explanation is also supported by the results of Schaefer, Koch, Opitz, von Herrath, and Knoop (29) who injected small doses of labeled vitamin D₃ (12.5 µg) into normal humans and patients with renal disease and found that unchanged vitamin D₃ represented only approximately 2% of the plasma-³H after 7 days. Moreover, more recently Mawer, Lumb, Schaefer, and Stanbury have reported that the disappearance rate of radioactive vitamin D₃ was slower in subjects receiving large doses of vitamin D than in patients relatively deficient in vitamin D (30).

By combining the results of the bioassay experiments with those of the turnover studies, an estimate can be obtained of the steady-state turnover of plasma 25-hydroxycholecalciferol in man. The bioassay studies suggested that the plasma samples contained 8–9 ng of cholecalciferol per ml and an amount of 25-hydroxycholecalciferol with bioactivity equivalent to 10–11 ng of cholecalciferol per ml. The biological activity of 25-hydroxycholecalciferol has been reported to be 1.4 times (3) and 1.78 times (8) that of cholecalciferol, on a per unit mass basis. By using a mean of these values, we can conclude that the samples bioassayed contained approximately 7 ng of 25-hydroxycholecalciferol per ml. If we now estimate the plasma volume as 3 liters and the extravascular (and extracellular) compartment as being similar to that for serum albumin (1.4 times the intravascular compartment [31]), we can estimate the sizes of the intravascular and extravascular pools of 25-hydroxycholecalciferol. These calculations indicate that the plasma compartment contained a total of approximately 21 µg, and the extravascular compartment a total of approximately 29 µg, giving a total extracellular pool of approximately 50 µg of 25-hydroxycholecalciferol. Given a half-life of 19.6 days and assuming a fully miscible extracellular compartment which behaved as a single pool during the later phase of the turnover study, these data suggest that the steady-state turnover of 25-hydroxycholecalciferol in the extracellular compartment was approximately 1.3 µg per day. This is equivalent to a steady-state turnover of 80–85 IU of biological activity per day. A comparable estimate cannot be made for vitamin D₃ itself because of the likelihood that the disappearance rate observed during the first days of study represented an unsteady state with regard to the turnover and metabolism of the labeled material.

The experiments reported here conclusively demonstrate that significant amounts of neither vitamin D nor its polar metabolite (presumably 25-hydroxycholecalciferol) circulate in plasma in association with any of the known plasma lipoproteins. In each of the several time intervals studied, almost all (mean 94%) of the plasma radioactivity was found associated with the

Vitamin D Turnover and Transport in Man 2165
proteins of density greater than 1.21. A very small portion of the injected labeled vitamin D₃ was found in association with the plasma lipoproteins during the shortest time intervals studied. The bioassay experiments demonstrated that biological activity associated with both vitamin D₃ and with the 25-hydroxycholecalciferol-containing fraction, was found in association with the plasma proteins of density greater than 1.21. In contrast, cholesterol and other lipids (except for FFA [32] and lyssolecithin [33]) circulate in plasma mainly as part of plasma lipoprotein molecules with hydrated densities of less than 1.21 (23, 34). Since both cholecalciferol and its 25-hydroxy derivative are sterol derivatives and nonpolar lipophilic lipid alcohols, the fact that these molecules circulate in association with proteins of density greater than 1.21 provides presumptive evidence for the existence of a specific transport protein (or proteins) for these compounds.

This conclusion is supported by recent studies in our laboratory dealing with the transport of retinol (vitamin A alcohol) in plasma. Beginning with the observation that retinol circulates in plasma in association with proteins of density greater than 1.21, we were able to develop a fractionation sequence for the isolation of retinol-binding protein (RBP), the specific transport protein for plasma vitamin A (24). RBP has now been characterized to a considerable extent (24, 35, 36).

The plasma protein responsible for the transport of 25-hydroxycholecalciferol has been partly characterized with regard to apparent molecular size and to electrophoretic mobility. Since the plasma samples which were examined in these experiments contained almost all their radioactivity as the polar (25-hydroxy) metabolite, comparable information is not available about the transport protein for vitamin D₃ itself. It remains for future studies to determine whether the same or different proteins are responsible for the transport of vitamin D and of 25-hydroxycholecalciferol. Gel filtration on Sephadex G-200 indicated that the polar metabolite (presumed to be 25-hydroxycholecalciferol) circulates in association with a protein of apparent molecular size very close to, but slightly smaller than, that of human plasma albumin. The mol wt of the protein can be estimated as approximately 50,000-60,000. On polyacrylamide gel electrophoresis the transport protein displayed mobility very slightly greater than that of plasma albumin. If we assume that the protein contains one binding site for one molecule of 25-hydroxycholecalciferol and that the protein circulates almost entirely as the holo-protein containing a molecule of bound 25-hydroxycholecalciferol, then the concentration of the transport protein would be of the order of 1 mg/liter of plasma. These assumptions are based upon our experience with plasma RBP (24, 36). Should plasma vitamin D₃ be transported by the same protein, then the level of the protein in plasma would be of the order of 2-3 mg/liter. Studies are in progress in our laboratory in an attempt to further fractionate and characterize the transport protein.

ACKNOWLEDGMENTS

We are grateful to Dr. D. Schachter and Mr. S. Kowarski for instruction in the vitamin D bioassay method. We thank Doctors P. Milch and Y. Muto for constructive criticism and assistance with the bioassay. Mrs. M. Bloom provided technical assistance. We thank Dr. J. C. Babcock of the Upjohn Co. for the gift of 25-hydroxycholecalciferol.

This work was supported by grant AM-05968 from the National Institutes of Health.

REFERENCES

15. Thomas, W. C., Jr., H. G. Morgan, T. B. Connor, L. Haddock, C. E. Bills, and J. E. Howard. 1959. Stud-


